Seegene Expands European Presence with New French Subsidiary to Enhance Diagnostics

Seegene's New French Subsidiary: A Strategic Expansion in Europe

Seegene, Inc., a global leader in molecular diagnostics (MDx), has announced the establishment of a new subsidiary in France. This development marks a significant milestone for the company as it seeks to enhance its presence in the European market and support its global sales growth.

The French Market'

France becomes the eighth international sales subsidiary for Seegene, and notably, the third in Europe, following the establishments in Italy and Germany. France holds a significant place in the European MDx landscape, being the second-largest market, only behind Germany. Recent market research indicates that the French MDx market could reach approximately €600 million, making up about 15% of the European total. This indicates a robust demand for diagnostic testing, particularly for sexually transmitted infections (STIs), gastrointestinal tract infections, and respiratory viruses.

The new subsidiary aims to capitalize on this demand, expanding sales for existing product lines and introducing a wider range of diagnostic solutions. This includes important areas like cervical cancer detection and multiplex diagnostics, which are crucial for enhanced patient care.

Enhancing Local Engagement and Support

Establishing the French subsidiary is not just about sales; it's also about fostering closer relationships with local customers and partners. Seegene emphasizes the importance of providing tailored technical support, improving market development efforts, and collaborating with stakeholders in the healthcare sector. This commitment to local engagement is expected to boost customer services and drive faster adoption of innovative diagnostic solutions like CURECA™ and STAgora™, which are currently in development.

Daniel Shin, Executive Vice President and Global Head of Sales and Marketing at Seegene, articulated, "In the private and public sectors of the French market, delivering innovative products and responding to the laboratories' efficiency needs is critical to maintaining competitiveness." By understanding the nuances of the healthcare landscape in France, Seegene aims to enhance its local service prowess, accelerating its growth in the in vitro diagnostics sector.

Strategic Growth in Europe

The French subsidiary presents a strategic foothold for launching Seegene's innovative solutions in Europe. CURECA™, an automated and autonomous PCR system, and STAgora™, a real-time diagnostic data analytics and prediction platform, are poised to make significant impacts in diagnostics upon their release.

With France's addition to its network, Seegene now boasts eight international sales subsidiaries, complementing its global distribution network, which includes 90 distributors across 94 countries. In the first half of 2025, approximately 93% of Seegene's total revenue was generated from international sales, with Europe accounting for a substantial 63%. This reinforces the region's critical role as a growth driver in the company's global expansion strategy.

Conclusion

Seegene's commitment to expanding its footprint in France highlights its proactive approach towards increasing accessibility to critical diagnostic technologies. As the company continues to develop and refine its products, the establishment of a local subsidiary in France underscores its dedication to enhancing diagnostic capabilities in Europe and beyond. Through strategic partnerships and local solutions, Seegene is set to revolutionize the diagnostic industry, ensuring that healthcare providers have access to cutting-edge technology to address emerging health challenges.

Disclaimer: CURECA™ and STAgora™ are currently under development and are not available for diagnostic use.

About Seegene

With over 25 years of experience in R&D and manufacturing related to real-time syndromic PCR technologies, Seegene gained significant recognition during the COVID-19 pandemic, supplying over 340 million COVID-19 tests to more than 100 countries. The cornerstone of Seegene's real-time syndromic PCR technology is its ability to analyze up to 14 pathogens simultaneously in a single tube, delivering quantitative insights. For more information, visit Seegene's website and follow them on LinkedIn.